Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
Enveric Biosciences, Inc. (ENVB)
Company Research
Source: Business Wire
Patent provides added depth to Enveric’s EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that on March 17, 2026, it received U.S. Patent No. 12,577,232 (“the’232 patent”) from the United States Patent and Trademark Office (USPTO) pertaining to its EVM301 Series of molecules. The EVM301 Series includes lead candidate, EB-003, being developed as potential treatments for mental health disorders.Entitled, “N-heterocycle substituted tryptamine derivatives and methods of using,” the patent adds to the portfolio covering Enveric’s EVM301 Series of molecules. The issued patent claims chemical compounds, pharmaceutical drug formulations, and methods
Show less
Read more
Impact Snapshot
Event Time:
ENVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENVB alerts
High impacting Enveric Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ENVB
News
- Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq RulesBusiness Wire
- Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq RulesBusiness Wire
- Enveric Biosciences GAAP EPS of -$6.12 [Seeking Alpha]Seeking Alpha
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 [Yahoo! Finance]Yahoo! Finance
ENVB
Sec Filings
- 4/20/26 - Form 8-K
- 4/14/26 - Form ARS
- 4/14/26 - Form DEFA14A
- ENVB's page on the SEC website